CHMP Backs Six-Weekly Cemiplimab Dosing Across EU Indications
The CHMP has issued a positive opinion backing six-weekly cemiplimab dosing across all EU indications, potentially halving annual infusion visits.
Topic
Regeneron
Topic
Regeneron
Sanofi Commits Up to $8B to Broaden Regeneron Antibody Alliance
Sanofi has committed up to $8 billion to expand its antibody-development partnership with Regeneron. The renewed agreement center…
Sanofi Signs New $8 Billion Pact with Regeneron
Sanofi has signed a new $8 billion pact with Regeneron, extending the alliance behind Dupixent and signaling further investment i…
Sanofi and Regeneron Re-Up Alliance as Dupixent Patent Cliff Nears
Sanofi and Regeneron renew their Dupixent alliance ahead of the patent cliff, AstraZeneca commits $2B to Summit, and Lilly report…
Sanofi Pays Regeneron $1B Upfront to Build Next-Gen Dupixent Successors
Sanofi will pay Regeneron $1 billion upfront, plus up to $7 billion in milestones, to co-develop four long-acting antibodies targ…
Regeneron and Sanofi Expand Immunology Partnership in Deal Worth Up to $8 Billion
Regeneron and Sanofi will add next-generation long-acting immunology antibodies to their collaboration in a milestone-based deal…